Cg Oncology, Common Stock Price Prediction
| CGON Stock | 33.90 0.05 0.15% |
Oversold Vs Overbought
49
Oversold | Overbought |
EPS Estimate Current Year (1.59) | EPS Estimate Next Year (1.89) | Wall Street Target Price 68.2 | Quarterly Revenue Growth 1.727 |
Using CG Oncology, hype-based prediction, you can estimate the value of CG Oncology, Common from the perspective of CG Oncology, response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in CG Oncology, to buy its stock at a price that has no basis in reality. In that case, they are not buying CGON because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
CG Oncology, after-hype prediction price | USD 33.99 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
CGON |
CG Oncology, After-Hype Price Prediction Density Analysis
As far as predicting the price of CG Oncology, at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in CG Oncology, or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of CG Oncology,, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
CG Oncology, Estimiated After-Hype Price Volatility
In the context of predicting CG Oncology,'s stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on CG Oncology,'s historical news coverage. CG Oncology,'s after-hype downside and upside margins for the prediction period are 31.22 and 36.76, respectively. We have considered CG Oncology,'s daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
CG Oncology, is very steady at this time. Analysis and calculation of next after-hype price of CG Oncology, Common is based on 3 months time horizon.
CG Oncology, Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as CG Oncology, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CG Oncology, backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with CG Oncology,, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.09 | 2.77 | 0.09 | 0.00 | 6 Events / Month | 3 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
33.90 | 33.99 | 0.27 |
|
CG Oncology, Hype Timeline
CG Oncology, Common is currently traded for 33.90. The entity has historical hype elasticity of 0.09, and average elasticity to hype of competition of 0.0. CGON is estimated to increase in value after the next headline, with the price projected to jump to 33.99 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 0.27%, whereas the daily expected return is currently at -0.09%. The volatility of related hype on CG Oncology, is about 15388.89%, with the expected price after the next announcement by competition of 33.90. The company reported the previous year's revenue of 204 K. Net Loss for the year was (48.61 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next estimated press release will be in about 6 days. Check out CG Oncology, Basic Forecasting Models to cross-verify your projections.CG Oncology, Related Hype Analysis
Having access to credible news sources related to CG Oncology,'s direct competition is more important than ever and may enhance your ability to predict CG Oncology,'s future price movements. Getting to know how CG Oncology,'s peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how CG Oncology, may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ELYM | Eliem Therapeutics | 0.25 | 4 per month | 0.00 | (0.19) | 6.21 | (9.35) | 34.87 | |
| SCPH | Scpharmaceuticals | (0.1) | 7 per month | 0.00 | (0.21) | 4.05 | (7.09) | 20.70 | |
| MIST | Milestone Pharmaceuticals | 0.05 | 7 per month | 1.61 | 0.09 | 7.19 | (2.11) | 18.66 | |
| MCRB | Seres Therapeutics | (0.06) | 9 per month | 5.66 | 0.02 | 10.84 | (9.78) | 28.84 | |
| LUMO | Lumos Pharma | (0.05) | 6 per month | 2.72 | 0.05 | 5.95 | (5.19) | 16.25 |
CG Oncology, Additional Predictive Modules
Most predictive techniques to examine CGON price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for CGON using various technical indicators. When you analyze CGON charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About CG Oncology, Predictive Indicators
The successful prediction of CG Oncology, stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as CG Oncology, Common, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of CG Oncology, based on analysis of CG Oncology, hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to CG Oncology,'s market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to CG Oncology,'s related companies. | 2010 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 0.0705 | 579.03 | 164.61 | 198.32 | PTB Ratio | 61.53 | 19.79 | 0.87 | 0.83 |
Story Coverage note for CG Oncology,
The number of cover stories for CG Oncology, depends on current market conditions and CG Oncology,'s risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that CG Oncology, is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about CG Oncology,'s long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
CG Oncology, Short Properties
CG Oncology,'s future price predictability will typically decrease when CG Oncology,'s long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of CG Oncology, Common often depends not only on the future outlook of the potential CG Oncology,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CG Oncology,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.3 M | |
| Cash And Short Term Investments | 187.7 M |
Check out CG Oncology, Basic Forecasting Models to cross-verify your projections. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.036 | Quarterly Revenue Growth 1.727 |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.